Reduction in Recurrence From Aromatase Inhibitors in Premenopausal ER+ Breast Cancer
December 08, 2021

Utilizing aromatase inhibitors compared with tamoxifen reduce recurrence in estrogen receptor-positive breast cancer in patients who were menopausal and received ovarian suppression.

Black Women Experience More Treatment Modifications Than White Women With Breast Cancer
December 08, 2021

Black patients may have poorer outcomes during breast cancer treatment than White patients.

FDA Approves FoundationOne CDx as Companion Diagnostic for BRAF Inhibitor Regimens in Melanoma
December 08, 2021

FoundationOne CDx has been approved by the FDA as a companion diagnostic for patients with melanoma undergoing treatment with a BRAF inhibitor.

Standard HER2 Assays Do Not Accurately Identify HER2-Low Breast Cancer
December 08, 2021

Data collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.

First-line Ribociclib Plus Letrozole Improved Survival for Postmenopausal HR+, HER2- Advanced Breast Cancer
December 08, 2021

Research presented at the 2021 San Antonio Breast Cancer Symposium highlighted survival improvements for postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer when treated with ribociclib plus letrozole over placebo.

Association Observed Between Higher Oncotype DX Scores Completion of Endocrine Therapy for Breast Cancer
December 08, 2021

Those with higher Oncotype DX scores may be more likely to complete the recommended 5 years of endocrine therapy for breast cancer.

Pooled Analysis Supports Palbociclib Use in Black and Hispanic Patients With HR+, HER2– Breast Cancer
December 08, 2021

Pooled efficacy and safety data confirm that patients who self-identify as Black or Hispanic can be safely treated with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.

EFS Improved With Neoadjuvant and Adjuvant Pembrolizumab Across Subgroups of Patients With Early-Stage TNBC
December 08, 2021

Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.

Successes and Challenges with Maintenance Therapy
December 08, 2021

Shilpa Gupta, MD and Jason Brown, MD discuss trials with successful or negative results with maintenance therapy.

Positive Response Activity Seen With Datopotamab Deruxtecan in Advanced TNBC
December 08, 2021

Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.